1 MRD at the end of induction
therapy of 10(-2) cells or more was predictive of an unf
2 ation (alloHCT) and single-agent maintenance
therapy of 12 months is feasible and favorably influence
3 ange, 1-71) were transplanted after bridging
therapy of 195 HCCs by stereotactic RFA (SRFA).
4 and potential clinical benefits, combination
therapies of (
223)Ra with microtubule-stabilizing cytoto
5 nd 104 had a CR to their last platinum-based
therapy; of 350 patients without a confirmed gBRCAmut (n
6 had no recurring symptoms under maintenance
therapy of 5 mg prednisolone during the 3-year follow up
7 and median overall survival after third-line
therapy of 5-9 months.
8 to better treat BPH patients who failed the
therapy of 5alpha-reductase inhibitors.
9 Combination direct-acting antiviral
therapy of 8-24 weeks is highly effective for the treatm
10 iplatelet drug, 1.28 (95% CI, 1.13-1.44) for
therapy of a direct oral anticoagulant with an antiplate
11 Combination
therapy of a HER2 inhibitor and an AKT inhibitor, as wel
12 the potential for epigenetic differentiation
therapy of a solid tumour through EZH2 inhibition.
13 tant implications for targeted pharmacologic
therapy of a wide range of cutaneous diseases.
14 Combinatorial
therapy of a WNT inhibitor with doxorubicin synergistica
15 as a promising strategy for allele-specific
therapy of ABCC6-associated calcification disorders.
16 Results Combination
therapy of ACE (angiotensin-converting enzyme) inhibitor
17 orbidities on 1-year mortality after initial
therapy of acute myeloid leukemia (AML) and (2) a novel,
18 Effective
therapy of acute myeloid leukemia (AML) remains an unmet
19 We do not yet have etiology-based
therapies of AD, but we continue to gain insight into th
20 rgic potentiators for pro-neurogenic or cell
therapies of AD.
21 ffering new therapeutic opportunities in the
therapy of AD and other neurodegenerative diseases assoc
22 role for resveratrol in the prophylaxis and
therapy of AD.
23 a provide a rationale to explore combination
therapy of adoptive HSPC-NK cells and DAC in patients wi
24 nib has been successfully established in the
therapy of advanced melanoma.
25 biomarkers, functional imaging, and systemic
therapy of advanced NETs and discuss results of recent p
26 rexed or bevacizumab is used for maintenance
therapy of advanced nonsquamous non-small-cell lung canc
27 yntenin (SDCBP) provides a direct target for
therapy of aggressive cancers such as GBM, and defined s
28 BCL patients participating in the PET-Guided
Therapy of Aggressive Non-Hodgkin Lymphomas trial, iPET
29 49 patients participating in the "PET-Guided
Therapy of Aggressive Non-Hodgkin Lymphomas" trial were
30 ur findings have clear implications for gene
therapy of airway disorders where plasmid DNA transfecti
31 The
therapy of all B-NHL is based on the combination of diff
32 immune cells was dispensable for successful
therapy of allergic airway inflammation (AAI) with dexam
33 rgenicity would allow improved diagnosis and
therapy of allergies and would provide insights for safe
34 l target pairings hold great promise for CAR
therapy of AML.
35 n essential chemotherapeutic backbone in the
therapy of AML.
36 d Blinded Investigation With Optimal Medical
Therapy of Angioplasty in Stable Angina).
37 r therapy in mice, tumor PS and photothermal
therapy of anti-CD11b Abs-linked gold nanorods (GNRs-CD1
38 e disparities in access to renal replacement
therapy of any kind and in the use of transplantation or
39 NJ5MUT could allow noninvasive diagnosis and
therapy of APAs carrying KCNJ5 mutations.
40 he two commonly used artemisinin combination
therapies of artesunate plus amodiaquine and artemether
41 d provide effective strategies for potential
therapies of ASD.
42 d tumor growth kinetics, whereas combination
therapy of aspirin and a PI3K inhibitor further attenuat
43 , opening prospects for diagnosis and causal
therapy of asthma.
44 a promising new target in the prevention and
therapy of atherosclerosis and thrombosis.
45 Chimeric antigen receptor (CAR) T-cell
therapy of B-cell malignancies has proved to be effectiv
46 nery has become an established target in the
therapy of B-cell malignancies.
47 he wild green variety is used in the initial
therapy of benign prostatic hyperplasia (BPH), globally.
48 instance, the therapeutic window for lithium
therapy of bipolar disorder is very narrow, and more fre
49 ctive radionuclide for use in targeted alpha
therapy of blood-borne diseases and micrometastatic dise
50 boost MSCs population required for stem cell
therapy of bone defects.
51 rrector could serve as a new pharmacological
therapy of both congenital and drug-induced K(v)11.1 tra
52 Combination interstitial
therapy of both paclitaxel and everolimus significantly
53 hesis, and its enhancement has potential for
therapy of both primary and secondary causes of hyperamm
54 unmet need for well-tolerated and effective
therapy of BPSD.
55 Conventional radiation
therapy of brain tumors often produces cognitive deficit
56 d evolving strategies for local and systemic
therapy of breast cancer.
57 yanine green (ICG), were developed for local
therapy of breast cancer.
58 promising multifunctional platform for local
therapy of breast cancers.
59 on of ER-alpha with CaM may be useful in the
therapy of breast carcinoma.
60 dichotomous immune responses relevant to the
therapy of cancer and autoimmunity.
61 ve been successfully applied in the clinical
therapy of cancer and represent a potential new class of
62 essential to the prevention, diagnosis, and
therapy of cancer associated with the expression of Tn.
63 act in conjunction with chemo- or radiation
therapy of cancer cells.
64 as ideal miniature reactors for photodynamic
therapy of cancer cells.
65 portant role for the CD28/B7 pathway in PD-1
therapy of cancer patients.
66 s proposed as a novel target for the (immuno)
therapy of cancer since A(2B)AR blockade results in anti
67 Therapy of cancer with radiolabeled monoclonal antibodie
68 ant challenges to the diagnosis and clinical
therapy of cancer.
69 hibitors are promising drugs for the (immuno)
therapy of cancer.
70 rkably well suited for targeted radionuclide
therapy of cancer.
71 en-specific T cell immunity for personalized
therapy of cancer.
72 g this approach for the targeted imaging and
therapy of cancers.
73 ll bispecific (TCB) antibody and combination
therapy of CEA-TCB (RG7802) and CEA-targeted 4-1BB agoni
74 rgets in PDAC treatments, including targeted
therapies of cellular processes such as proliferation, e
75 12D, an important genetic marker for guiding
therapy of certain cancers.
76 port the potential utility of (R)-BPO-27 for
therapy of CFTR-mediated secretory diarrheas.
77 etronidazole, vancomycin and fidaxomicin are
therapies of choice for Clostridium difficile infection.
78 rcome before LVADs will be considered as the
therapy of choice for all patients with advanced heart f
79 matopoietic stem cell transplantation is the
therapy of choice for patients with IPEX syndrome.
80 atform for the study of the pathogenesis and
therapy of cholangiopathies, particularly PSC.
81 vealed potential targets for pharmacological
therapies of cholestatic liver diseases.
82 lead to novel approaches for prevention and
therapy of cholesterol-driven neurodegenerative disease.
83 f SND in the population, new pharmacological
therapies of chronic SND and heart block are desirable.
84 age infections and protocols for maintenance
therapy of chronic infections.
85 Adoptive cell
therapy of chronic lymphocytic leukemia (CLL) with chime
86 Clinically, combined
therapy of cisplatin (CDDP) and metformin is an effectiv
87 2014 and now is used for initial and salvage
therapy of CLL patients.
88 open up new perspectives for efficient gene
therapy of cochlear and vestibular disorders by showing
89 Despite advances in the detection and
therapy of colorectal cancer (CRC) in recent years, CRC
90 The
therapy of complex neurodegenerative diseases requires t
91 In our case, the initial combination
therapy of corticosteroids plus mesalazine followed by a
92 ole for nAbs in prophylaxis, and potentially
therapy, of COVID-19.
93 R monoclonal antibody therapies for targeted
therapy of CRC.
94 a promising drug candidate for total cancer
therapy of CRCs.
95 Here, we propose that a combination
therapy of current antiglioma regimens and autophagic me
96 vide a mechanistic rationale for combination
therapy of CXCR4 and BCL-2 inhibitors to treat a common
97 3/4 adverse events compared with the doublet
therapy of dabrafenib, trametinib and placebo.
98 . melitensis infected mice with the standard
therapy of daily 0.5 mg doxycycline dose or single 0.5 m
99 Recent clinical studies on combination
therapy of decitabine (DAC) and arsenic trioxide (ATO) h
100 CFTR inhibitor (R)-BPO-27 for antisecretory
therapy of diarrheas caused by bacterial enterotoxins.
101 is and even the possibility for simultaneous
therapy of diseases caused by bacterial infections.
102 Immediate diagnosis and appropriate
therapy of dissecting aneurysms is necessary for good cl
103 In adoptive
therapy of disseminated leukemia, CD200R-CD28-transduced
104 This may constitute a novel target for
therapy of DMCM.
105 myosarcoma can be inhibited by combinatorial
therapy of DNMTi and dasatinib, laying the groundwork fo
106 The combination
therapy of docetaxel and C3 receptor antagonist disrupte
107 onment could serve as a ray of light for the
therapy of drug-resistant infections.
108 duodenoscopy (EGD) or their first endoscopic
therapy of early neoplastic BE, from April 2015 through
109 clinical study opens avenues for a potential
therapy of early-stage septic shock.
110 n important consideration for prevention and
therapy of enteric disease.
111 48 hours or <=48 hours of APBL for empirical
therapy of Enterobacteriaceae BSI after adjustment for t
112 orm could be exploited to guide personalized
therapy of EOC and is potentially transferrable to other
113 ntibiotic resistance may involve combination
therapies of existing antibiotics and potentiating adjuv
114 ed Tasmanian devils, and regression followed
therapy of experimentally induced DFTD tumours in three
115 rected HSPCs, opening new prospects for gene
therapy of FA patients.
116 Drug
therapy of FAT is often difficult and ineffective.
117 The targeting and
therapy of gastrointestinal stromal tumors (GIST) using
118 n in antibiotic-treated mice, and antibiotic
therapy of germ-free mice caused no additional abnormali
119 To date current
therapies of glioblastoma multiforme (GBM) are largely i
120 Antiangiogenic
therapy of glioblastoma (GBM) with bevacizumab, a VEGFA-
121 ood-brain barrier (BBB) after antiangiogenic
therapy of gliomas with bevacizumab may result in a decr
122 Y/RKIP interaction is a potential target for
therapy of gliomas.
123 suggest consideration of applying a combined
therapy of GLS inhibitor and PARP inhibitor to treat che
124 seltamivir, shows promise for prophylaxis or
therapy of group I and II IAVs with pandemic potential.
125 d favorable pharmacokinetics for imaging and
therapy of GRPR-expressing tumors.
126 eceptor 4 (CXCR4) is attractive for targeted
therapy of haematological cancers, given its expression
127 cladribine, has been the standard first-line
therapy of hairy cell leukemia (HCL) for 30 years.
128 may be a rational target for anti-angiogenic
therapy of HCC.
129 The prevention, diagnosis and
therapy of HCMV infection are thus crucial to public hea
130 led a new pathway for the molecular targeted
therapy of HD.
131 hallenges to proper positioning in radiation
therapy of head and neck cancers.
132 ventricle (LV) to guideline-directed medical
therapy of heart failure, perhaps due to interventricula
133 become useful targets for the diagnostics or
therapy of heart failure.
134 ion in two mouse models of allogeneic T-cell
therapy of hematopoietic and solid cancers.
135 IFNalpha-based antiviral
therapy of hepatitis delta was independently associated
136 Differential diagnosis and
therapy of heterogeneous breast tumors poses a major cli
137 l novel biomarkers and targets for precision
therapy of HNSCC.
138 rug target for inducing immunosuppression in
therapy of human disease as well as a rapidly emerging d
139 onal research as they may allow modeling and
therapy of human diseases in vivo.
140 tal mouse model for studying the biology and
therapy of human marginal-zone B-cell lymphomas.
141 Here, we describe a novel method for
therapy of hyperinsulinemic hyperglycemia, highly select
142 rovides information for planning radioiodine
therapy of hyperthyroidism.
143 otherapy or PTT, the combinational chemo-PTT
therapy of ICG-EPI NPs with NIR laser irradiation synerg
144 tyrate, two pillars of recommended long-term
therapy of individuals with urea cycle disorders (UCDs),
145 t of improved strategies for CPE control and
therapy of infections.
146 rs have strong potential applications in the
therapy of inflammation and, likely, of autoimmune disea
147 2-PP2A axis as a potential target for future
therapy of inflammation-associated diseases such as meni
148 serious infections due to available medical
therapies of inflammatory bowel disease (IBD) remains co
149 tion the use of nicotinamide riboside in the
therapy of inflammatory disorders.
150 texture, we demonstrate that a combinatorial
therapy of intermittent C, CI, and vinorelbine activates
151 EMD
therapy of intrabony defects promotes additional benefit
152 ion when compared with standard single-agent
therapy of investigator's choice in Checkmate 141; here
153 -of-life outcomes compared with single-agent
therapy of investigator's choice in patients with platin
154 ading of leukocytes may hold promise for the
therapy of IPA.
155 herefore aid studies of the pathogenesis and
therapy of IPF.
156 Combination
therapy of ISF35 with systemic anti-PD-1 generates great
157 e last workforce study in the prevalence and
therapy of liver diseases and training may impact workfo
158 vitro, a major limitation for the cell-based
therapy of liver disorders and for ex vivo biological sc
159 of HNF4alpha in LR and have implications for
therapy of liver failure.
160 rd ATRA and chemotherapy (CHT) in first-line
therapy of low- or intermediate-risk acute promyelocytic
161 Here we show that a combination
therapy of low-dose anti-CD3 with a clinical-grade self-
162 A reduction in dFLC after
therapy of &
lt;10 mg/L was associated with a better OS and
163 D8 T cells proliferating in blood after PD-1
therapy of lung cancer patients were predominantly CD28-
164 n using magnetic particles for diagnosis and
therapy of lung cancers: (i) a combination of magnetic p
165 ontributes information for the diagnosis and
therapy of LV thrombus after STEMI.
166 Conventional oral
therapy of lymphatic filariasis drugs is only effective
167 per group were treated with (a) combination
therapy of magnetic resonance imaging heating guidewire-
168 ications is exemplified here as photodynamic
therapy of malignancies.
169 Gene
therapy of malignant gliomas has shown a lack of clinica
170 advances have been made in the diagnosis and
therapy of malignant small round cell tumors that affect
171 led antibody for imaging and a surrogate for
therapy of malignant tissues expressing PSMA.
172 reatment but will also be beneficial for the
therapy of many other solid tumors.
173 Therapy of melanoma patients harboring activating mutati
174 Thus, nMET is essential to precision
therapy of MET inhibitor.
175 des novel potential targets for the clinical
therapy of metabolic bone diseases.
176 pecific defects, paves the way for precision
therapy of metabolic diseases.
177 SMA) is an excellent target for radionuclide
therapy of metastasized castration-resistant prostate ca
178 rly effective: first is in the diagnosis and
therapy of metastatic bone cancer, in which radioactive
179 posomal doxorubicin (CREKA-Lipo-Dox) for the
therapy of metastatic breast tumor.
180 , due to their significance in prognosis and
therapy of metastatic cancer.
181 by (124)I PET/CT-based dosimetry for (131)I
therapy of metastatic DTC when the same patient was prep
182 s THW patient preparation methods for (131)I
therapy of metastatic DTC.
183 Experimental
therapy of mice bearing peritoneal MKN-45P xenografts an
184 ammatory cells, indicating a potential novel
therapy of MSC-Exo for uveitis.
185 vora, these phages are of interest for phage
therapy of multidrug-resistant pathogens.
186 proach for making antigen-specific Tregs for
therapy of multiple diseases.
187 inhibitors (PI) are extensively used for the
therapy of multiple myeloma (MM) and mantle cell lymphom
188 e an experimental basis for exosome-mediated
therapy of muscle atrophy and renal fibrosis.
189 develop the next-generation vectors for gene
therapy of muscle disorders, given the relatively modest
190 ugs inhibiting MNT could significantly boost
therapy of MYC-driven tumors by enhancing intrinsic MYC-
191 y of drugs and drug combinations for initial
therapy of myeloma as well as maintenance approaches pos
192 guidance on the lifestyle and pharmacologic
therapies of NAFLD, and the consensus position on alcoho
193 this unmet clinical need, the pharmacologic
therapy of NAFLD has been expanding as the varied mechan
194 cids (BA) are linked to the pathogenesis and
therapy of NASH.
195 The diagnosis and subsequent
therapy of neuroendocrine neoplasms (NENs) have long rel
196 availability and use of DOTA analogs in the
therapy of neuroendocrine tumors, we expect that (68)Ga-
197 intigraphy and peptide receptor radionuclide
therapy of neuroendocrine tumors.
198 c gene editing has significant potential for
therapy of neuromuscular disorders.
199 pyrrolo[2,3-d]pyrimidine antifolate used for
therapy of nonsquamous nonsmall cell lung cancer (NS-NSC
200 work develops a plasmid DNA approach to gene
therapy of NPC1 using Trojan horse liposomes (THLs), whe
201 his study prospectively compared combination
therapy of olanzapine plus either samidorphan or placebo
202 gnaling, viability, and response to targeted
therapies of oncogene-addicted cells.
203 CT guided RA
therapy of OO is minimally invasive, effective and secur
204 hophysiology, timing, impact on outcome, and
therapy of organ failure in acute pancreatitis.
205 can also contribute to the understanding and
therapy of other IDDs.
206 which may have utility for RNA interference
therapy of other tumors or brain diseases.
207 P) chemotherapy is a promising post-surgical
therapy of ovarian cancer, but the full potential is yet
208 the advantages of synchronized interstitial
therapy of paclitaxel and everolimus for post-surgical t
209 MAS in childhood may inform study design for
therapy of PALF.
210 Combination
therapy of papilla preservation, connective tissue graft
211 nitor cells (hBTSCs) are being used for cell
therapies of patients with liver cirrhosis.
212 udy aimed to assess whether NT-proBNP-guided
therapy of patients with acute decompensated HF using a
213 of ganetespib and docetaxel for second-line
therapy of patients with advanced adenocarcinoma of the
214 not result in improved survival for salvage
therapy of patients with advanced-stage lung adenocarcin
215 ng via MET and CD44 during anti-EGF receptor
therapy of patients with colorectal cancer or in patient
216 f (68)Ga-PSMA-11 PET for planning (223)RaCl2
therapy of patients with metastatic prostate cancer and
217 The
therapy of patients with relapsed/refractory (R/R) B-NHL
218 relevance for the diagnosis, prognosis, and
therapy of patients.
219 ature-based subtyping may guide personalized
therapy of PDAC in the context of biomarker-driven prosp
220 ration of and confer resistance to radiation
therapy of PDAC.
221 ongoing management, and empirical antifungal
therapy of pediatric FN were reviewed; the most substant
222 that miR-96 might be a potential target for
therapy of pediatric SE.
223 laser irradiation for regenerative surgical
therapy of peri-implantitis-associated osseous defects.
224 ent treatable traits in addition to targeted
therapy of PH and underlying causes.
225 tionale: Antimicrobial resistance challenges
therapy of pneumonia.
226 atherothrombotic events, which makes aspirin
therapy of potential value in these subjects.
227 ionale to use Pin1 inhibitor(s) for targeted
therapies of PrCa patients with wild-type SPOP.
228 Combined approach
therapy of PRF + 1% ALN for IBD treatment in patients wi
229 ood-brain barrier for targeting, imaging and
therapy of primary and metastatic tumors of the brain.
230 est that development of a long-term curative
therapy of prostate cancer may be possible by killing an
231 ble interest as a target for diagnostics and
therapy of prostate cancer patients.
232 on to existing ligands proposed for targeted
therapy of prostate cancer, RPS-027 has tumor-to-tissue
233 PSMA is a target for the imaging and
therapy of prostate cancer.
234 aimed to identify key principles of targeted
therapy of protein kinases and their application to the
235 Molecular mechanisms and
therapies of PSCC are understudied, owing to scarcity of
236 s a promising cytokine-independent target in
therapy of psoriasis and psoriatic arthritis.
237 fore represents an attractive target for the
therapy of RA.
238 tform, named TCZ-PNPs, for PA-imaging-guided
therapy of RA.
239 icient photosensitizers for the photodynamic
therapy of ras-driven cancers.
240 cell-based system for targeted suicide gene
therapy of recurrent, metastatic, and unresectable ovari
241 9 on bacteriophage and phage-encoded protein
therapies of relevance to clinical microbiology.
242 The primary
therapy of renal cancer is the surgical removal.
243 l find application for antibody-based cancer
therapy of ROR2-expressing neoplasms.
244 ferroptosis in vitro and in vivo Combination
therapies of SCD1 inhibitors and ferroptosis inducers si
245 early diagnosis and the development of novel
therapies of schizophrenia.
246 an direct research into the pathogenesis and
therapy of seemingly unrelated common diseases.
247 o neurodegeneration to be useful targets for
therapy of senile dementias.-Goetzl, E.
248 aling is considered a rational target in the
therapy of several cancers, particularly those harbourin
249 ase complex (IKK) has been implicated in the
therapy of several chronic inflammatory diseases includi
250 senting the most significant progress in the
therapy of several malignancies depend on the presence o
251 cal course, and offer prospects for curative
therapy of sickle cell disease.
252 tion of SMN exon 7 inclusion for a potential
therapy of SMA.
253 monitoring for early detection and effective
therapy of SMNs.
254 y be an important adjunct to standard cancer
therapy of solid tumors.
255 might be a candidate for molecular targeted
therapies of SSc.
256 s remain about the role of DAPT in long-term
therapy of stable post-myocardial infarction (MI) patien
257 Current
therapies of steroid hormone-dependent diseases predomin
258 Combination
therapy of steroids and NSAIDs had no added benefit over
259 Treatment with combination
therapy of steroids and NSAIDs showed no added benefit o
260 is study was to test a novel neuromodulation
therapy of stimulation of epicardial cardiac nerves pass
261 and its regulators as potential targets for
therapies of T cell-mediated autoimmunity.
262 ty of using CD7 CAR T cells for the targeted
therapy of T-cell malignancies.
263 I peptides is a promising ASATI approach for
therapy of T1D.
264 models revealed that TACE and a combination
therapy of TACE and sorafenib were significant prognosti
265 e no effective drug delivery systems for the
therapy of TAD.
266 e results strengthen the possibility that co-
therapy of temozolomide with a CA XII inhibitor may more
267 HDAd5/35++ vectors for in vivo gene
therapy of thalassemia had a unique capsid that targeted
268 may provide a source of cells for cell-based
therapies of the inner ear.
269 is antigen a suitable target for radioligand
therapy of the disease.
270 illustrates the substantial progress made in
therapy of the disease.
271 ing cell engraftment and thus improving cell
therapy of the infarcted myocardium.
272 Subsequent
therapy of the lead proband with a MEK inhibitor led to
273 n-specific T cell responses are critical for
therapy of these diseases.
274 JP4-039 is a promising strategy for adjuvant
therapy of these disorders.
275 evelopment of new experimental drugs for the
therapy of these disorders.
276 medicine and in decision making for targeted
therapy of these tumors.
277 ers, our finding may open a path towards the
therapy of these tumours.
278 suggest novel avenues for the prevention or
therapy of this common arrhythmia.
279 lead to new strategies for the diagnosis and
therapy of this disease.
280 could potentially be used for prevention and
therapy of this group of diseases.
281 d reviews focused on the pathophysiology and
therapy of this syndrome, the role of arterial stiffness
282 hrombotic drugs, for both the prevention and
therapy of thrombotic complications.
283 Radioiodide (RAI)
therapy of thyroid cancer exploits the relatively select
284 icagrelor and were randomized to maintenance
therapy of ticagrelor (n=56) or prasugrel (n=54) after p
285 phocholine (NM600) for targeted radionuclide
therapy of TNBC.
286 ate the DLN as a target for immunomodulatory
therapy of transplant rejection.
287 infection and as a target for host-directed
therapy of tuberculosis.
288 ergistic radio-/X-ray inducible photodynamic
therapy of tumors is reported.
289 three symptomatic patients with median prior
therapies of two (range, one to nine therapies), of whom
290 l programs assessing GPR119 agonists for the
therapy of type 2 diabetes.
291 When compared to combination
therapy of vancomycin and aztreonam, delafloxacin was no
292 of exosomes and their role in prognosis and
therapy of various diseases and the above results contri
293 ing molecular target used in the imaging and
therapy of various types of cancers.
294 Combined cell
therapy of vessel-forming cells and renal tubule-forming
295 Early intervention with a combination
therapy of vildagliptin plus metformin provides greater
296 ection of the lung is a step toward targeted
therapy of VZV-induced disease.
297 n prior therapies of two (range, one to nine
therapies), of whom 40% were refractory to their previou
298 467 patients recruited, 428 started medical
therapy, of whom 400 (93%) were evaluable at 52 weeks an
299 erapy and 255 assigned to avoid antiplatelet
therapy, of whom one withdrew and was not analysed) and
300 We designed a trial in which postremission
therapy of young patients with de novo acute myeloid leu